We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · December 01, 2020

Empagliflozin Decreases CV Complications and Hospitalizations in Patients With T2D and ASCVD

The Lancet Diabetes & Endocrinology

 

Additional Info

The Lancet Diabetes & Endocrinology
Effects of Empagliflozin on First and Recurrent Clinical Events in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: A Secondary Analysis of the EMPA-REG OUTCOME Trial
Lancet Diabetes Endocrinol 2020 Dec 01;8(12)949-959, DK McGuire, B Zinman, SE Inzucchi, C Wanner, D Fitchett, SD Anker, S Pocock, S Kaspers, JT George, M von Eynatten, OE Johansen, W Jamal, M Mattheus, U Elsasser, S Hantel, SS Lund

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading